Recovery Tracker May Reduce Readmissions After Gynecologic Cancer Debulking

Video

Patients who use a recovery tracker tool appear to experience lower hospital readmission rates following gynecologic cancer debulking surgery compared with those who did not.

At The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, Jacqueline Feinberg, MD, spoke with CancerNetwork® about findings from a retrospective review assessing the effectiveness of a recovery tracker in detecting complications and reducing unplanned hospital visits for patients who underwent debulking surgery for ovarian or endometrial cancer, or uterine sarcoma.

In the review, 8% of patients in the recovery tracker cohort—a digital tool designed to track patient-reported symptoms for the first 10 days at home after discharge—experienced complications higher than grade 2 vs 4% of patients who did not have a tracker (P = .303). Additionally, 3% of those who used the tracker were readmitted compared with 10% of those who did not use the tracker (P = .049).

Feinberg, a gynecologic oncology fellow at Memorial Sloan Kettering Cancer Center, said that the exploratory analysis would need to be confirmed in a randomized, controlled trial.

Transcript:

Once we had the data of patients who used the recovery tracker, what we did was pair that with data of patients who had debulking surgeries over that same period of time—the 1-year period from June 2021 to 2022—with patients who also underwent debulking surgery but chose to not enroll in the recovery tracker. They went through a similar recovery after their surgeries, but were not answering the symptom questions.

The questions we had was, for the patients who ultimately chose to use the recovery tracker, is that associated with fewer visits to the hospital—i.e urgent care visits and lesser need for readmission/readmission rates? And then, [the question of] if there’s any relationship to actually having a severe complication.

Really, this is an exploratory analysis. It’s data that wasn’t meant to be paired for this. It’s going to be hypothesis-generating more than anything else. We did find that there was an association with reduced readmission rates and patients who used the recovery tracker compared with those who didn’t. [There was] also a trend towards fewer complications in those patients, although, it wasn’t statistically significant.

This is, like I said, hypothesis-generating. If we were to do a randomized controlled trial in the future where some patients use the recovery tracker vs those who don’t, we would certainly want to define these outcomes from the get-go. But the theory behind why this may have an impact is that we’re catching things earlier. That means we can deal with things with patients at home; we can give them the medications they need at home without them having to come back into the hospital, go away from their families, and [deal with] everything that entails.

Reference

Feinberg J, Zivanovic O, Kim SH, et al. Patient-reported symptoms after debulking surgery and associations with urgent care visits, readmissions, and complications. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content